Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association Annual Meeting.
In this video, Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association (AUA) Annual Meeting, taking place May 3-6 in San Antonio, Texas. Shore is the US chief medical officer of urology/surgical oncology at GenesisCare USA, as well as the director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.